High dose immunosuppressive therapy and stem cell transplantation in autoimmune and inflammatory diseases

International Immunopharmacology

Volumn 2, Issue 4, 2002, Pages 399-414

  Bingham, Sarah J ^a   Snowden, John ^a   Morgan, Gareth ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Autoimmune disease; Stem cell transplantation

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETANERCEPT; ETOPOSIDE; FLUDARABINE; GADOLINIUM; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; STEROID; THIOTEPA; THYMOCYTE ANTIBODY;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; AUTOTRANSPLANTATION; BONE MARROW TRANSPLANTATION; CROHN DISEASE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; PEMPHIGUS VULGARIS; POLYCHONDRITIS; POLYMYOSITIS; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULCERATIVE COLITIS; WEGENER GRANULOMATOSIS; WHOLE BODY RADIATION;

AUTOIMMUNE DISEASES; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; STEM CELL TRANSPLANTATION;

EID: 0036180307     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(01)00191-6     Document Type: Review

References (108)

1. Immune ablation followed by allogenic of autologous bone marrow transplantation: A new treatment for severe autoimmune diseases?
2. Stem cell transplantation in autoimmune disease
3. BMT for severe autoimmune diseases: An idea whose time has come
4. Autologous haemopoietic stem cell transplantation: A possible cure for rheumatoid arthritis?
5. Haemopoietic stem cell transplantation for autoimmune diseases
6. Stem cells transplantation - A cure for autoimmune diseases
7. Stem cell transplantation for severe autoimmune diseases: Progress and problems
8. Bone marrow transplantation in patients with gold-induced marrow aplasia
9. Long-term outcome of autoimmune disease following allogenic bone marrow transplantation
10. Progression of rheumatoid arthritis following bone marrow transplantation
11. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for haematological malignancy
12. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation
13. Autologous stem cell transplantation in a lymphoma patient with a long history of ankylosing spondylitis
14. Pure red cell aplasia complicating an ABO-compatible allogenic bone marrow transplantation, treated successfully with antithymocyte globulin
15. Prolonged remission of longstanding systemic lupus erythematosis after autologous bone marrow transplant for non-Hodgkin's lymphoma
16. Blast crisis of chronic myelogenous leukaemia in long-lasting systemic lupus erythematosus: Regression of both diseases after autologous bone marrow transplantation
17. Autologous PBSCT in a patient with lymphoma and Sjogren's syndrome: Complete remission without control of the autoimmune disease
18. Remission of nonerosive polyarthritis associated with Sjogren's syndrome after autologous hemopoietic stem cell transplantation for lymphoma
19. Haemopoietic stem cell transplantation (HSCT) in a patients with Sjogren's syndrome and lung malt lymphoma cured lymphoma not the autoimmune disease
20. Allogenic bone marrow transplantation for chronic myelogenous leukaemia in a patient with multiple sclerosis
21. Allogenic stem cell transplantation for chronic myelogenous leukaemia in two patients with multiple sclerosis
22. Clinical remission of myasthenia gravis (MG) in a patient (PT) after high-dose therapy and autologous transplantation with CD34+ stem cells (SC)
23. Resolution of autoimmune hepatitis after bone marrow transplantation
24. Course of Crohn's disease after allogeneic marrow transplantation
25. Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease
26. Prolonged clinical remission in patients (pts) with inflammatory bowel disease (IBD) after high dose chemotherapy (HDC) and autologous blood stem cell transplantation (ABSCT)
27. Resolution of immune mediated diseases following allogenic bone marrow transplantation for leukaemia
28. Autoimmune thrombocytopenia in a patient with small cell lung cancer developing after chemotherapy and resolving following autologous peripheral blood stem cell transplantation
29. Autologous CD34+ cells transplantation after FAMP treatment in a patient with CLL and persisting AIHA: Complete remission of lymphoma with control of autoimmune complications
30. Immunoregulation rather than immunosuppression for prevention and treatment of autoimmune disorders
31. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy
32. Blood and marrow stem cell transplants in autoimmune disease: A consensus report written on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Bone Marrow Transplantion (EBMT)
33. Autologous haemopoietic stem cell transplantation for severe autoimmune disease with special reference to rheumatoid arthritis
34. Composition and function of peripheral blood stem and progenitor cell harvested from patient with severe active rheumatoid arthritis
35. A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilization in patients with severe active rheumatoid arthritis
36. Autologous bone-marrow transplantation for rheumatoid arthritis
37. A phase I study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of haemopoietic progenitor cells in active rheumatoid arthritis
38. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor
39. Mobilization of peripheral blood stem cells in patients with autoimmune disease
40. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe active rheumatoid arthritis
41. Autologous hemopoietic stem cell transplantation in refractory rheumatoid arthritis: Sustained response in two of four patients
42. Intensive immunoablation and autologous blood stem cell transplantation in patients with refractory rheumatoid arthritis: The University of Nebraska experience
43. Remission and immune reconstitution after T-cell-depleted stem cell transplantation for rheumatoid arthritis
44. Autologous T cell-depleted CD34+ peripheral blood stem cell transplantation in four patients with refractory rheumatoid arthritis and juvenile chronic arthritis
45. Autologous stem cell transplantation for rheumatoid arthritis - Interim report of six patients
46. High-dose chemotherapy and autologous stem cell transplantation in patients with rheumatoid arthritis: Results of an open study to assess feasibility, safety and efficacy
47. High-dose chemotherapy and syngeneic hemopoietic stem-cell transplantation for severe, seronegative rheumatoid arthritis
48. 2) cyclophosphamide and granulocyte colony-stimulating factor administration for haemopoietic stem cell mobilization in refractory rheumatoid arthritis
49. Collection of hemopoietic stem cells from patients with autoimmune diseases
50. Marked and sustained improvement two years after autologous stem cell transplantation in a girl with systemic sclerosis
51. Efficacy and safety of autologous peripheral blood stem cell transplantation in three children with systemic sclerosis and progressive pulmonary involvement
52. High dose cyclophosphamide followed by autologous peripheral blood stem cell transplantation for the treatment of systemic sclerosis
53. High-dose chemotherapy plus T cell-depleted autologous stem cell transplantation for the treatment of systemic sclerosis
54. High-dose immunosuppressive therapy (HDIT) with autologous stem cell transplantation (SCT) for systemic sclerosis (SSc): Results in the first 8 patients
55. Long-term follow-up after high dose cyclophosphamide and CD43+-selected aPBSCT for progressive systemic sclerosis (PSS)
56. Autologous haemopoietic stem cell transplantation in a patient with severe pulmonary hypertension complicating connective tissue disease
57. Leeds experience of stem cell transplantation for autoimmune disease
58. Autologous CD34-selected peripheral blood stem cell transplantation in a young patient with severe systemic sclerosis
59. Autologous stem cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells
60. Cardiac death after autologous stem cell transplantation (ASCT) for treatment of systemic sclerosis (SSc): No evidence for cyclophosphamide-induced cadiomyopathy
61. Phase I/II trail of autologous stem cell transplantation in systemic sclerosis: Procedure-related mortality and impact on skin disease
62. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration
63. Stem cell transplantation for resistant lupus
64. Autologous stem cell transplantation in a case of treatment-resistant central nervous system lupus
65. Autologous blood and marrow cells transplantation in chronic GVHD and in autoimmune diseases
66. Autologous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome
67. Control of severe systemic lupus erythematosus after high dose immunosuppressive therapy and transplantation of CD34+-purified autologous stem cells from peripheral blood
68. Autologous blood stem cell therapy for autoimmune pancytopenia due to systemic lupus erythematosus
69. Graft-failure in a patient with systemic lupus erythematosus (SLE) treated with high dose immunosuppression and autologous stem cell rescue
70. Prolonged remission without treatment after autologous stem cell transplantation for refractory childhood systemic lupus erythematosus
71. Autologous haemopoietic stem cell transplantation in four patients with refractory juvenile chronic arthritis
72. Infection-associated MAS in 3 patients receiving ASCT for refractory juvenile chronic arthritis
73. Intense immunosuppression followed by purified blood CD34+ cell autografting in a patient with refractory juvenile rheumatoid arthritis
74. Effective treatment of Jo-1-associated polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation
75. Autologous stem cell transplantation for rapidly progressive Jo-1-positive polymyositis with long-term follow-up
76. Autologous stem cell transplantation in patients with severe rheumatic diseases: A pilot study
77. First experience with a new protocol for haematopoietic stem cell mobilization (MOB) and transplantation in patients (pts) with autoimmune diseases (AD)
78. Immune reconstitution post autologous stem cell transplantation (ASCT) for paediatric vasculitis and resulting changes in autoimmune disease profile
79. Prolonged remission of refractory adult-onset Still's disease following CD34-selected autologous peripheral blood stem cell transplantation
80. Autologous stem cell transplantation in progressive multiple sclerosis - An interim analysis on efficacy
81. T cell-depleted autologous hematopoietic stem cell transplantation in patients with severe autoimmune diseases
82. Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS
83. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS
84. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: Report of toxicity and immunological monitoring
85. Autologous CD34+-selected peripheral stem cell transplantation (ASCT/CD34+) for multiple sclerosis (MS)
86. High dose immunosuppressive therapy with PBSC support in the treatment of poor risk multiple sclerosis
87. Autologous peripheral blood progenitor cell transplantation in multiple sclerosis: A phase I/II clinical trial
88. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: A consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation: BMT-MS study group
89. Immune ablation and stem cell transplantation for severe Evans syndrome and refractory thrombocytopenic pupura
90. Peripheral blood stem cell transplantation for refractory autoimmune thrombocytopenic purpura
91. Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura
92. Autologous peripheral bool stem cell transplantation in a patient with chronic autoimmune thrombocytopenia
93. Treatment of severe Evans syndrome with an allogeneic cord blood transplant
94. Immunoablative high-dose cyclophosphamide without stem cell rescue in a patient with pemphigus vulgaris
95. Complete remission in severe aplastic anaemia after high dose cyclophosphamide without bone marrow transplantation
96. Immunoablative high dose cyclophosphamide without stem cell rescue for refractory, severe autoimmune disease
97. High-dose immunoablative cyclophosphamide in SLE
98. High dose chemotherapy without autologous stem cell reinfusion in the treatment of RA
99. Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE): Treatment and induction of tolerance, with high dose cyclophosphamide followed by syngeneic bone marrow transplantation
100. Syngeneic bone marrow transplantation eliminates V beta 8.2 T lymphocytes from the spinal cord of Lewis rats with experimental allergic encephalomyelitis
101. Xenograft tolerance
102. Molecular mimicry and autoimmune diseases
103. Common infections, idiotypic dysregulation, autoantibody spread and induction of autoimmune diseases
104. Immunologic phenotype and function in bone marrow, blood stem cells and umbilical cord blood
105. Reconstitution of the haemopoietic and immune system after marrow transplantation
106. A detailed study on immune recovery in 50 patients autotransplanted with blood progenitor cells
107. Constraints on CD4+ recovery postchemotherapy in adults: Thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells
108. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant haematological diseases